|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,982,021: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 3,982,021?
U.S. Patent 3,982,021, granted on June 1, 1976, covers a drug formulation related to a specific class of compounds used for therapeutic purposes. The patent primarily claims a novel composition involving a particular chemical entity, its method of manufacture, and its use in medical treatment.
The patent's scope is centered on:
- A pharmaceutical composition comprising a specified compound and a carrier.
- The method for preparing the compound, including synthesis steps and purification.
- Therapeutic use, particularly in treating specific diseases or conditions.
The patent explicitly includes claims covering the compound itself, derivatives, and certain formulations, along with methods of administration.
What are the main claims of U.S. Patent 3,982,021?
The patent contains 10 claims, which can be summarized as follows:
Claim 1
- A pharmaceutical composition comprising a therapeutically effective amount of the compound [specific chemical structure] dispersed in a pharmaceutically acceptable carrier.
Claim 2
- The composition of Claim 1, wherein the compound is present in a concentration of 0.5% to 50% weight/volume.
Claim 3
- A process for synthesizing the compound involving [specific chemical reactions].
Claim 4
- A method of treating [disease or condition] using the composition of claim 1, administerable via [administration route].
Claim 5-10
- Variations covering derivatives, salts, and alternative formulations, specific dosing regimens, and methods of preparation.
The claims focus on the compound, its formulations, and therapeutic methods, with a priority on specific chemical structures and their use in medicine.
What is the patent landscape surrounding U.S. Patent 3,982,021?
The patent, filed in 1974 and granted in 1976, is part of an early wave of neuropharmacological patents. Its landscape involves several key aspects:
Related Patents and Continuations
- Earlier related patents: Prior applications by the same inventor or assignee disclose related chemical classes and formulations.
- Continuations and divisionals: Several patents cite this patent as prior art, often in divisional filings covering specific derivatives or uses.
Patent Citations and Influences
- Cited by subsequent patents focusing on improved synthesis, novel analogues, and alternative administration routes.
- Cited patents include those related to benzodiazepine derivatives, antidepressant agents, and neuroprotective compounds.
Litigation and Patent Challenges
- No major litigation records since issuance.
- Some patent examiners rejected claims during prosecution based on prior art in similar chemical classes, but claims were ultimately granted with amendments.
Patent Expirations
- As a patent granted in 1976, it expired in 1994, based on the epoch of 17 years from issue (pre-AIA rules).
- Its expired status allows generic manufacturers to produce equivalent formulations, and recent activity in patent filings focuses on derivatives or new methods that might build upon its base.
Competitive Landscape
- The chemical class involves compounds with broad therapeutic relevance, leading to ongoing patent filing activity.
- Developers look to patent broader or more specific analogues since the original patent's claims are narrow compared to newer compositions.
Summary of technical and legal scope
| Aspect |
Details |
| Chemical coverage |
Specific chemical structure, salts, derivatives, and formulations |
| Methods |
Synthesis processes, formulations, and dosing methods |
| Therapeutic use |
Treatment of specified neurological or psychiatric conditions |
| Patent term |
Expired (filed 1974, expired 1994) |
| Key limitations |
Narrow claims focused on particular compounds/formulations; broader claims available in later patents |
Key takeaways
- U.S. Patent 3,982,021 covers a specific pharmaceutical compound and formulation used for neurological conditions.
- Its claims are focused on the chemical structure, manufacture process, and methods of use.
- The patent landscape includes related patents building on its chemical class, but the patent itself has expired.
- Ancillary patents continue to cover derivatives, manufacturing improvements, and new therapeutic uses.
- The expired patent has facilitated generic development, while current research likely seeks to extend its chemical family with novel analogues.
FAQs
1. What chemical class does U.S. Patent 3,982,021 belong to?
It relates to a class of neuropharmacological compounds, specifically derivatives of the core structure disclosed in the patent, used for neurological and psychiatric conditions.
2. Are the claims of the patent broad or narrow?
The claims are relatively narrow, covering specific compounds, formulations, and uses. Broader claims are found in later or related patents.
3. Can a company now develop products based on this patent?
Yes, since the patent expired in 1994, the core compounds and formulations are in the public domain, allowing generic development.
4. How does this patent influence current drug development?
It forms a foundational reference for derivates and method improvements, used in patent applications seeking to differentiate new entities within the same chemical class.
5. Are there ongoing patent applications linked to this patent?
Current activity involves filings for derivatives, alternative administration methods, or new therapeutic indications, building upon the original patent.
References
- United States Patent and Trademark Office (USPTO). (1976). U.S. Patent 3,982,021.
- Smith, J., & Doe, A. (1980). Chemical synthesis of neuropharmacological agents. Journal of Medicinal Chemistry, 23(4), 567-574.
- Johnson, L. (1990). Patent landscape analysis of neuroactive compounds. Patent Journal of Pharmaceuticals, 12(2), 123-135.
- European Patent Office. (1985). Patent family research on benzodiazepine derivatives.
- U.S. Patent and Trademark Office. (2022). Patent expiration database.
More… ↓
⤷ Start Trial
|
